ArticleCancer management and research2026
Prognostic Factors in Upper Gastrointestinal Neuroendocrine Carcinoma: A Retrospective Cohort Study of Clinicopathological Features and Survival Outcomes.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Upper gastrointestinal neuroendocrine carcinoma (NEC) is a rare and highly aggressive malignancy with limited prognostic data. This study aimed to evaluate clinicopathological characteristics and to identify clinically relevant prognostic factors, with a particular focus on simple and readily available inflammatory and nutritional biomarkers that may support routine risk stratification. Methods: In this retrospective cohort study, 54 patients with histologically confirmed esophageal or gastric NEC were analyzed. Clinical, pathological, laboratory, treatment, and survival data were collected. Overall survival (OS) was assessed using Kaplan-Meier analysis. Prognostic factors were evaluated using univariate and multivariate Cox proportional hazards models. Results: The median OS was 17.9 months. On univariate analysis, metastatic disease, elevated LDH, elevated neutrophil-to-lymphocyte ratio (NLR), hypoalbuminemia, surgical resection, and adjuvant chemotherapy were significantly associated with OS. In multivariate analysis, hypoalbuminemia remained the only independent predictor of worse survival (HR 2.876, 95% CI 1.116-7.414; p = 0.029). Conclusion: Hypoalbuminemia emerged as a potential independent prognostic factor in this cohort and may serve as a simple and readily available marker of poor outcome. Albumin, LDH, and NLR may provide additional prognostic information in patients with upper gastrointestinal neuroendocrine carcinoma. However, these findings should be considered exploratory and require validation in larger prospective multicenter studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.